- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02903706
Prevalence of Malaria Parasites in People Working in Illegal Gold Mining in French Guiana (ORPAL)
Malaria is the most widespread parasitic illness in the world, and it is endemic to Guiana. Although the number of cases has decreased since 2005, sources of infection still remain, particularly within illegal gold mines. These malaria carriers/sufferers often use self-medication to deal with malaria symptoms, resulting in a risk of resistance to anti-malarial treatments, and particularly to artemisinine. The mobility of this population across the Guiana Shield increases both the risk of malaria spreading and the resistance of this illness to treatment in the region, and puts the population at risk of new outbreaks of this disease despite the great efforts put into anti-malarial policy in this region.
Fighting malaria within this population is therefore a dual public health challenge: on the one hand, make it possible for the WHO to eliminate malaria from the Guiana Shield by 2017, on the other to limit resistance to artemisinine in this region. However, Guiana's particular context - namely the illegal status of gold mines and the difficult geographical access, the Harpie military operations, the illegality of carrying out malarial diagnosis tests and treating cases without the presence of a health professional - prevents us from achieving this goal using the same tools as our neighbours in Suriname, whose " Looking for Gold, Finding Malaria " programme was a success.
A better understanding of the malarial epidemiology in this population will enable us to propose innovative, more adapted measures to combat malaria within these guyanese populations. This is an transversal, multicentric observational study.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Main Aim:
To estimate the prevalence of Plasmodium carriers in the population of illegal gold mine workers in French Guiana.
Secondary aims:
Evaluate the proportion of different Plasmodium species affecting this population and
- Determine parasitaemia levels;
- Evaluate the gametocyte index;
- Map the number and proportion of P. falciparum cases for the different river sites where gold mining is carried out;
- Determine the lifestyle, knowledge, attitude and behaviour of these populations concerning malaria;
- Estimate the prevalence of mutations linked to the resistance of parasites to artemisinine derivatives;
- Analyse the global genetic diversity of these parasites.
- Evaluate the global health of gold miners
The results of this study will make it possible to characterise the malaria epidemic in illegal gold-mining sites across French Guiana, evaluate the size of the human reservoir and the prevalence of ACT-tolerant parasites, identify the most urgent areas to be dealt with, suggest appropriate plans of action for this, and adopt more efficient public information campaigns.
Target Population: People working on illegal gold mining sites in French Guiana.
Inclusion Criteria:
- works on a gold mining site in French Guiana
- has been at the resting site for less than seven days
- is over the age of 18
- accepts to take part in this study
Exclusion Criteria:
- refuses to take part in the study
- is under the age of 18
The sampling of the 240 people needed for this study will be achieved through chance meetings and the resulting snowball effect at gold mining resting sites on the Surinamese banks of the Maroni river.
Study Protocol:
- Acquisition of authorisations from the competent French authorities
- Authorisation from the competent Surinamese authorities
- Recruitment of one mediator/translator, one state registered nurse and one doctor
- Collaboration with Dr Cairo (program "looking for gold, finding malaria) in Suriname to plan the field missions
- Teams from Suriname and French Guiana will work joinly in the field: eligible persons will be enrolled in the study, the others can be tested by the Surinamese team.
- Inclusion of subjects through chance meetings and the snowball effect at resting sites
- Consent of patients and checking of inclusion criteria
Performance of three diagnostic tests for each person, including
- an RDT on site
- If the RDT is positive: complete treatment given to patient following national guidelines;
If necessary, provision of a results sheet describing the necessary doses for treatment;
- Performance of thick and thin blood smears for transport to the CHAR parasitology laboratory for analysis;
- Collection of a 5ml (EDTA) tube of blood d'un tube de sang de 5ml reserved in an icebox between 4°C et 10°C for the CNR malarial parasitology lab at the Institut Pasteur de la Guyane;
- Completion of the questionnaire;
- Temperature is taken;
- Patient is provided with a brochure about malaria in Portugese and/or Sranantango;
- Provision of an insecticide-treated net.
Study Type
Enrollment (Actual)
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- works on a gold mining site in French Guiana
- has been at the resting site for less than seven days
- is over the age of 18
- accepts to take part in this study
Exclusion Criteria:
- refuses to take part in the study
- is under the age of 18
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Crossover
- Time Perspectives: Cross-Sectional
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
prevalence of malaria positive individuals (symptomatic or not symptomatic)
Time Frame: 1 month
|
every participant gives a capillary blood specimen which is then screened for malaria using PCR in order to obtain a prevalence of malaria positive individuals (symptomatic or not symptomatic)
|
1 month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Microscopy: thick and thin smear
Time Frame: 1 month
|
Each participant is screen for malaria using classic microscopy on thin and thick smears in order to obtain a prevalence of malaria positive individuals and to evaluate parasite quantities, and gametocyte carriage (transmission potential).
If either thin or thick smears are positive then the patient is estimated to have smear positive malaria.
|
1 month
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ORPAL
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Malaria
-
University of California, San FranciscoCenters for Disease Control and Prevention; University of Massachusetts, Amherst and other collaboratorsRecruitingPlasmodium Falciparum Malaria | Plasmodium Vivax MalariaLao People's Democratic Republic
-
Medicines for Malaria VentureAsociacion Civil Selva AmazonicaCompletedPlasmodium Falciparum Malaria | Plasmodium Vivax MalariaPeru
-
Menzies School of Health ResearchInternational Centre for Diarrhoeal Disease Research, Bangladesh; Addis Ababa... and other collaboratorsCompletedMalaria | Vivax Malaria | Falciparum MalariaEthiopia, Bangladesh, Indonesia
-
University of OxfordWellcome Trust; Ministry of public Health AfghanistanCompletedVivax Malaria | Uncomplicated Falciparum MalariaAfghanistan
-
Gadjah Mada UniversityMenzies School of Health Research; Eijkman Institute for Molecular Biology; Timika...Completed
-
Menzies School of Health ResearchNational Health and Medical Research Council, Australia; Wellcome Trust; National...CompletedVivax Malaria | Falciparum MalariaIndonesia
-
London School of Hygiene and Tropical MedicineWorld Health Organization; United Nations High Commissioner for Refugees; HealthNet... and other collaboratorsCompletedMalaria | Vivax Malaria | Falciparum MalariaPakistan
-
Menzies School of Health ResearchNational Health and Medical Research Council, Australia; Wellcome Trust; National...CompletedVivax Malaria | Falciparum MalariaIndonesia
-
University of IbadanShin Poong Pharm Co Ltd 161 yoksam-ro, Gangnam-Gu Seoul 135-925, Korea; Institute...CompletedPlasmodium Falciparum Malaria | Uncomplicated Malaria | Malaria FeverNigeria
-
Research Institute for Tropical Medicine, PhilippinesWorld Health OrganizationCompletedTES of Artemether-lumefantrine for Pf and Chloroquine for Pv in the Philippines From 2013-2014 (TES)Malaria | Vivax Malaria | Falciparum Malaria | Malaria Recrudescence
Clinical Trials on Measure of Plasmodium prevalence (PCR)
-
Centre Hospitalier Universitaire, AmiensUnknown
-
Uşak UniversityCompleted
-
Lund UniversitySkane University HospitalRecruiting
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Not yet recruiting
-
University Hospital, Clermont-FerrandUnknownSarcopenia | Chronic Heart FailureFrance
-
Polish Adult Leukemia GroupCompletedChronic Myeloid Leukemia
-
Centre Hospitalier Universitaire, AmiensCompletedAlzheimer Disease | Frontotemporal Dementia | Dementia, Vascular | Semantic Dementia | Huntington DiseaseFrance
-
Wyeth is now a wholly owned subsidiary of PfizerCompleted